Australia's Atomo Diagnostics hits over 2-month high on deal with French firm

Atomo Diagnostics

18/01/2023 24:52

** Shares of Atomo Diagnostics  AT1.AX  rise as much as 7.1%
to A$0.06, their highest since Nov. 9
    ** Medical device firm signs agreement with France-based NG
Biotech SAS to expand the launch of rapid blood-based pregnancy
tests 
    ** Under agreement, AT1 has secured exclusive distribution
rights for both professional and self-test versions of the
product in Australia, New Zealand, Canada and U.S.
    ** The agreement has an initial period of five years and
will renew for further five years unless terminated by either
party
    ** More than 620,000 shares have changed hands, vs the
30-day average of about 188,000 shares 
    ** AT1 stock down ~82% in 2022 
 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))